Next Article in Journal
Correction: Yunita et al. Scoping Review: The Role of Tocotrienol-Rich Fraction as a Potent Neuroprotective Agent. Int. J. Mol. Sci. 2025, 26, 7691
Previous Article in Journal
EV-Finder: Direct Detection of Extracellular Vesicle-Associated Proteins by Proximity Extension Assay for Multi-Cancer Screening
Previous Article in Special Issue
Evidence for a Potential Context-Dependent Dual Role of Eb Peptide of IGF-1Eb in Cancer Cell Survival and Adaptation to UV Stress
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Targeting Osteoporosis-Osteoarthritis Comorbidity: Multi-Omics Identification of SON and Exploration of Therapeutic Agents

1
Department of Orthopedic Surgery, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Road, Suzhou 215000, China
2
Department of Orthopedic Magnetic Resonance Chamber, The First Affiliated Hospital of Soochow University, No. 899 Pinghai Road, Suzhou 215000, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2026, 27(11), 4905; https://doi.org/10.3390/ijms27114905 (registering DOI)
Submission received: 1 March 2026 / Revised: 21 April 2026 / Accepted: 15 May 2026 / Published: 28 May 2026

Abstract

Osteoporosis (OP) and osteoarthritis (OA) frequently coexist in the elderly, yet shared molecular pathways remain unclear. We employed weighted gene co-expression network analysis (WGCNA), independent cohort differential verification, and integration of multiple datasets to explore the association between the two diseases and identify the hub genes. Then, through Mendelian randomization and single-cell sequencing methods, we confirmed that SON might be the key protein linking these two diseases and a promising therapeutic target for comorbidity. Additionally, this study utilized the FDA drug database for virtual screening to evaluate the potential of SON protein as a drug target. Nilotinib, with a high docking score, was listed as a candidate drug. Overall, our findings suggest that SON may play a protective role in the comorbidity of OP and OA, but further functional studies are required to confirm its causal role. Moreover, Nilotinib shows inhibitory effects on osteoclast differentiation and targets SON in vitro, indicating its potential as a candidate drug for further investigation.
Keywords: osteoporosis; osteoarthritis; targeted therapy osteoporosis; osteoarthritis; targeted therapy
Graphical Abstract

Share and Cite

MDPI and ACS Style

Jiang, K.; Du, J.; Yang, P.; Lin, L.; Liu, J.; Qiao, Y.; Yang, H.; Geng, D.; Li, K. Targeting Osteoporosis-Osteoarthritis Comorbidity: Multi-Omics Identification of SON and Exploration of Therapeutic Agents. Int. J. Mol. Sci. 2026, 27, 4905. https://doi.org/10.3390/ijms27114905

AMA Style

Jiang K, Du J, Yang P, Lin L, Liu J, Qiao Y, Yang H, Geng D, Li K. Targeting Osteoporosis-Osteoarthritis Comorbidity: Multi-Omics Identification of SON and Exploration of Therapeutic Agents. International Journal of Molecular Sciences. 2026; 27(11):4905. https://doi.org/10.3390/ijms27114905

Chicago/Turabian Style

Jiang, Kunlong, Jun Du, Peng Yang, Liyun Lin, Jiachen Liu, Yusen Qiao, Huilin Yang, Dechun Geng, and Kun Li. 2026. "Targeting Osteoporosis-Osteoarthritis Comorbidity: Multi-Omics Identification of SON and Exploration of Therapeutic Agents" International Journal of Molecular Sciences 27, no. 11: 4905. https://doi.org/10.3390/ijms27114905

APA Style

Jiang, K., Du, J., Yang, P., Lin, L., Liu, J., Qiao, Y., Yang, H., Geng, D., & Li, K. (2026). Targeting Osteoporosis-Osteoarthritis Comorbidity: Multi-Omics Identification of SON and Exploration of Therapeutic Agents. International Journal of Molecular Sciences, 27(11), 4905. https://doi.org/10.3390/ijms27114905

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop